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ABSTRACT
Background.Mitoxantronewasapproved foruse inmetastatic
castrate-resistant prostate cancer (mCRPC) based on pain
palliationwithout observed survival benefit in a small phase III
trial in 1996. To re-evaluate for possible survival benefits in
a larger contemporary sample and to demonstrate analytic
uses of the newly available Project Data Sphere online
resource, we used data from control arms of completed
clinical trials to compare survival and toxicity among patients
with postdocetaxel mCRPC treated with mitoxantrone and
prednisone.
Patients and Methods. Control arm data from two phase III
randomized control trials, SUN 1120 and TROPIC, were used
to examine the efficacy of mitoxantrone plus prednisone
(n5 305) versus prednisone alone (n5 257) among patients
with postdocetaxel mCRPC. Propensity score matching was
used to balance patient characteristics between the separate
trials, conditioned on age and key prognostic variables of
survival.The primary outcomewas overall survival. Secondary
endpoints evaluated safety.
Results.Median survival was similar among patients receiving
mitoxantrone plus prednisone versus prednisone alone
(385 days vs. 336 days; deceleration factor 5 0.04; 95%
confidence interval:20.12 to 0.22). Prevalence of several any-
grade toxicity, including fatigue, back pain, and peripheral
neuropathy, was increased among patients who received
mitoxantrone.
Conclusion.There was no significant survival benefit for
mitoxantrone plus prednisone over prednisone alone among
men with mCRPC after docetaxel therapy. This finding is
consistent with prior studies showing no survival advantage
with mitoxantrone in the predocetaxel setting. Furthermore,
our data suggest that mitoxantrone may be associated
with increased toxicity compared with prednisone alone.
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Implications for Practice: This study is the first to use clinical trial data from Project Data Sphere (PDS) to elucidate a current
question in clinical oncology that is independent from the questions that the trials were originally designed to assess. This study
illustrates the potential for comparative effectiveness research studies using PDS or similar repositories to answer questions for
which prospective studies may never be conducted.
INTRODUCTION
Mitoxantrone was approved by the U.S. Food and Drug
Administration (FDA) for use in metastatic castrate-resistant
prostate cancer (mCRPC) in 1996 based on a palliative benefit
with improvementinbonepainandeffectonanalgesicuse[1–3].
Nearly two decades ago, in a small phase III trial, 161 patients
with symptomatic mCRPC were randomized to mitoxantrone
plus prednisone versus prednisone alone; pain relief response
(the primary study outcome) was achieved in 29% of patients
treated with mitoxantrone versus 12% of patients treated with
prednisone,withnosurvivalbenefitobserved[3].Asecondstudy
of 242 mCRPC patients randomized to mitoxantrone plus hy-
drocortisone versus hydrocortisone alone suggested improve-
ment of pain severity and frequency with mitoxantrone but,
again, was unable to demonstrate a survival benefit [1]. A third
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multicenter clinical trial comparing prednisone and mitoxan-
trone plus prednisone in 2002 demonstrated more frequent
prostate-specific antigen (PSA) responses and longer time to
treatment failure among 120 men with mCRPC, with no sig-
nificant survival benefit for mitoxantrone [4].
Despite its purported palliative benefits, possible side
effects of mitoxantrone include gastrointestinal distress; my-
elosuppression; fever; pain; and, less commonly, acute my-
elogenous leukemia and congestive heart failure [3]. Since the
introduction of mitoxantrone in 1996, several therapeutic
options including taxanes have become available for use in
mCRPC. In theTAX327trial, docetaxelplusprednisoneshowed
a significant survival benefit of approximately 3 months com-
paredwithmitoxantroneplusprednisone inmCRPC, leading to
its FDA approval in 2004 [5]. Subsequently, cabazitaxel plus
prednisone resulted in prolonged survival compared with
mitoxantrone plus prednisone among patients with docetaxel
failure in the TROPIC trial [6]. Given these advances, the cur-
rent role and timing of mitoxantrone in the management of
patients with mCRPC are unclear.
No available data satisfactorily answer the question of
whethermitoxantroneoffers anybenefit, including survival, in
patients with postdocetaxel mCRPC. A prospective random-
ized study is unlikely to be conducted, given the availability of
newer agents (both approved and under study) and the lackof
interest in investigatingmitoxantrone in this setting. Nonethe-
less, mitoxantrone continues to be used in clinical practice
among patients with progressive mCRPC and remains a re-
quired standard of care comparator for prospective studies
investigating new agents in the post-taxane setting.
Comparative effectiveness research (CER) offers an op-
portunity to study the risks and benefits of competing stan-
dards of care outside the setting of prospective randomized
studies. To date, most CER has been performed in large ob-
servational registryor claims-baseddata sets that provide very
large numbers of exposed patients but may contain limited
patient-level characteristics [7] In contrast, the Project Data
Sphere (PDS) initiative represents a unique opportunity to
perform CER analyses using clinical trial-grade data. Currently,
comparator arm data from 14 clinical trials are available in the
PDS database, and 12 involve prostate cancer. Available trial
data can be pooled and analyzed using standard pharmacoe-
pidemiologic methods for bias reduction, allowing for cross-
trial comparisons of treatment effects.
To re-evaluate for possible survival benefits among
patients with mCRPC in a larger contemporary sample and to
demonstrate the potential analytic uses of the newly available
PDS online resource, we used data from control arms of com-
pleted clinical trials in PDS to compare survival and toxicity
betweenmitoxantrone plus prednisone and prednisone alone
among patients with postdocetaxel mCRPC.We hypothesized
that the combination of mitoxantrone plus prednisone would
not be associated with a survival benefit when comparedwith
prednisone alone in this mCRPC postdocetaxel population.
PATIENTS AND METHODS
Study Overview and Design
In this retrospective cohort study,we reanalyzeddata fromthe
control armsof twophase III randomized controlled trials, SUN
1120 and TROPIC. SUN 1120 was initiated in 2008 to evalu-
ate the safety and efficacy of sunitinib in combination with
prednisone versus placebo and prednisone among 873
patients with mCRPC that progressed after treatment with
docetaxel-based chemotherapy [8, 9]. The experimental arm
(n5584) received sunitinib37.5mg/dayorally plusprednisone
5 mg twice daily, whereas the comparator arm (n 5 289)
received a placebo plus prednisone 5mg twice daily. SUN1120
was terminated prematurely on September 27, 2010, due to
evidence that the combination of sunitinib plus prednisone
was unlikely to improve overall survival compared with
prednisone during a scheduled interim analysis.
The TROPIC trial, published in 2010, examined the safety
and efficacy of cabazitaxel plus prednisone compared with
mitoxantrone plus prednisone among 755 patients with
mCRPC after disease progression with docetaxel-based
chemotherapy [10]. All participants were treated with
prednisone 10 mg daily. The experimental arm (n 5 378)
received cabazitaxel 25 mg/m2 intravenously over 1 hour
every 3 weeks, whereas the comparator arm (n 5 377)
received mitoxantrone 12 mg/m2 intravenously over 15–30
minutes. Patients were treated until disease progression,
death,unacceptable toxicity,or foramaximumof10cycles. For
both trials, theprimaryoutcomewasoverall survival. Inclusion
and exclusion criteria for SUN 1120 and TROPIC are outlined in
the supplemental online Appendix.
In the present study, control arm data from the SUN 1120
and TROPIC trials were used to examine the efficacy of mi-
toxantrone plus prednisone compared with prednisone alone
among the patients with mCRPC refractory to docetaxel.
Study Population
There were 289 patients in SUN 1120 and 377 patients in
TROPICwhowerepotentially eligible for inclusion in this study.
In order to ensure the comparability of the patients across
these two trials, we limited our samples from each trial by
excluding those who would not have been eligible for both
trials. Specifically, we excluded patients with Eastern Co-
operative Oncology Group (ECOG) scores of 2 because TROPIC
allowed scores of 2 and SUN 1120 did not. Patients were also
excluded if they were missing covariate information on any of
the key variables for our analysis (Fig. 1). This resulted in 562
total patients, including 305 patients treated with mitoxan-
trone plus prednisone (TROPIC) and 257 patients treated with
prednisone alone (SUN 1120), who were eligible for inclusion
in our analysis.
Measures
The primary outcome of interest was overall survival. Overall
survival was considered from the date of randomization to the
date of death from any cause, with amedian follow-up time of
12.8 months in TROPIC and 8.7 months in SUN 1120.
For the outcomes of interest, we controlled for covariate
data collected at baseline within each trial. Covariates
included age and prognostic variables of survival in the
postdocetaxel, second-line chemotherapy setting [11]. The
prognostic variables included in our analysis included doce-
taxel treatment within the last 6 months, ECOG perfor-
mance status (0 or 1), hemoglobin, serum PSA level, and
measurable disease (presence of a lesion .10 mm on spiral
www.TheOncologist.com ©AlphaMed Press 2015
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computed tomography or .20 mm on conventional com-
puted tomography).
The secondary endpoint was a comparison of safety data
fromeach trial. Adverseevents (AEs)were gradedaccording to
the National Cancer Institute Common Terminology Criteria
for Adverse Events version 3.0. AEs, physical exams, hematol-
ogy, biochemistry, vital signs, and electrocardiograms were
monitored throughout both studies. Left ventricular ejection
fraction was monitored throughout the TROPIC trial in
mitoxantrone-treated patients. For the purpose of this study,
we focused on themost common AEs among any grade, grade
2, and grade$3.
Statistical Analysis
Propensity Score Estimation and Application
Because our study integrates data from two distinct trials, we
lost thebenefitof randomassignment fromtheparenttrials.To
balance characteristics of patients from the separate trials, we
used propensity scorematching.We estimated the propensity
score by modeling the probability of being in the prednisone
arm versus the mitoxantrone plus prednisone arm, condi-
tioned on the key covariates described above, using the R
package MatchIt [12]. From 257 patients treated with
prednisone and 305 patients treated with mitoxantrone plus
prednisone, a comparable subset of 198 patients was selected
from each study (match percentage of 76%). In evaluating the
differences between patients who were matched and those
who were not within each treatment group, we found that in
both SUN 1120 and TROPIC, recent docetaxel, higher ECOG
performance status, and higher hemoglobin were associated
with being matched. Matched patients were older than
unmatched patients in SUN 1120, whereas matched patients
were younger than unmatched patients in TROPIC. These
matched subsets were used in all subsequent analyses to
assess the effects of mitoxantrone on survival of patients with
progressive postdocetaxel mCRPC.
Survival Analysis
SAS version 9.3 (SAS Institute Inc., Cary, NC, http://www.sas.
com) was used for all analyses. The Cox proportional hazards
assumptionwasnotmet forall covariates included inourstudy,
thus the survival analysis was performed using an accelerated
failure time model with Weibull distribution. Deceleration
factorsand95%confidence intervals (CIs)werecalculatedwith
an accelerated failure time model for the primary outcome of
overall survival. Patients contributed time to the analysis until
the date of death, disenrollment, or the end of the study.We
had 80% power to detect a median survival difference of 25%
between patients treated with mitoxantrone plus prednisone
versus patients treatedwithprednisone alone (a5 .05). In our
secondary analysis of safetydata,weevaluated theprevalence
of adverse events occurring over a period of 28.7 months, the
follow-up time from start to completion of the shorter trial in
our analysis, SUN 1120.
Sensitivity Analysis
To ensure the robustness of our findings, we considered two
alternative survival models. The first model used the pro-
pensity score-matched sample and did not adjust further for
covariates, which were shown to be balanced, in our matched
cohort. In the second model, we added each of the matching
covariates to ensure that there was no residual confounding
when using the propensity score matched sample. Results
were consistent across these twomodels, thus we present the
results from only the former model.
Figure1. CONSORTdiagram.Measurabledisease if a lesion.10mmwasobservedon spiral computed tomography (CT) or.20mmwas
observed on conventional CT.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; Hgb, hemoglobin; PSA, prostate-specific antigen.
©AlphaMed Press 2015
TheOncologist®
518 Mitoxantrone Plus Prednisone for mCRPC
RESULTS
Baseline Characteristics
Prior to propensity score matching, patients in the two trials
differed on several baseline characteristics (Table 1). On
average, for example, patients in the mitoxantrone plus
prednisone group were younger, had higher body mass index,
were more likely to be white, and were less likely to include
patients identified as “other” race compared with the
prednisonegroupalone. Patients alsodiffered in their baseline
hemoglobin levels and ECOG performance status prior to
matching. After matching, patients were similar to one
another on all measured characteristics, with the exception
of other race.
Outcome
There was no significant difference in overall survival among
those receiving mitoxantrone plus prednisone compared
with those receiving prednisone alone in the accelerated
failure time model. Median survival among patients who
received mitoxantrone plus prednisone was 385 days com-
pared with 336 days among patients who received predni-
sone alone (Fig. 2) (deceleration factor50.04; 95%CI:20.12
to 0.22). Match status was not a significant predictor of
overall survival in either treatment group. Adjustment for
matching covariates in themodel had no significant effect on
the results.
Safety or Toxicity
Common toxic effects ofmitoxantrone plus prednisone versus
prednisone alone are outlined in Table 2. A higher proportion
of grade$3 neutropenia and neutropenic fever (3% vs. none)
was reported among patients receiving mitoxantrone plus
prednisone versus prednisone alone. A higher prevalence of
anemia, amongall grades,wasnotedamongpatients receiving
prednisone alone, including 4% with grade $3 toxicity
categorized as anemia. Among any-grade AE, fatigue (45% vs.
26%), peripheral neuropathy (17% vs. 8%), dyspnea (12% vs.
6%), and back pain (29% vs. 22%) weremore prevalent among
patients receivingmitoxantroneplus prednisone. Anygradeof
left ventricular dysfunction was also higher among those
receiving mitoxantrone compared with patients receiving
prednisone alone (9% vs. ,1%). Both groups had ,1% of
patients with grade $3 toxicity related to left ventricular
dysfunction.
DISCUSSION
In this retrospective analysis comparing control armdata from
two large, previously published randomized clinical trials,
there was no significant survival benefit formitoxantrone plus
prednisone versus prednisone alone among men with mCRPC
after docetaxel therapy. This finding is consistent with prior
studies showing that mitoxantrone does not offer a survival
advantage in the predocetaxel setting. Fatigue, peripheral
neuropathy, dyspnea, and back painwere alsomore prevalent
among patients receiving mitoxantrone plus prednisone.
Table1. Comparisonofcharacteristicsofpatientstreatedwithmitoxantroneplusprednisoneversusprednisonealone,beforeand
after propensity score matching propensity score matching
Characteristic
Before propensity score matching After propensity score matching
Prednisone
Mitoxantrone
plus prednisone p value Prednisone
Mitoxantrone
plus prednisone p value
Patients, n 261a 312a 198 198
Age, years, mean (range) 68 (47–86) 66 (47–85) .04 68 (47–86) 67 (49–85) .78
Race (%)
White 75 83 .03 77 82 .21
Black 5 6 .63 4 6 .35
Asian 9 8 .76 8 9 .85
Other 11 3 ,.01 12 3 ,.01
BMI, kg/m2, median (range) 27 (18.2–54) 28 (17.6–46.8) .02 28 (18.2–54) 28 (17.6–46.8) .77
PSA, ng/mL, median (range) 153 (0.2–5,927) 107 (1.7–11,220) .56 129 (0.6–5,927) 120 (1.7–11,220) .44
ECOG performance status score (%) ,.01 .84
0 129 (50) 101 (33) — 81 (41) 84 (42) —
1 128 (50) 202 (67) — 117 (59) 114 (58) —
Metastatic sites (%)
Bone 229 (89) 262 (86) .41 175 (88) 172 (87) .76
Visceral/soft tissue 101 (39) 135 (45) .24 82 (41) 96 (48) .19
Bone and visceral/soft tissue 83 (32) 112 (37) .29 66 (33) 82 (41) .12
Hemoglobin, g/dL, median (range) 12.0 (8.3–16.0) 12.0 (7.6–16.0) ,.01 12.1 (8.9–15.0) 12.1 (7.6–5.4) .77
Alkaline phosphatase, U/L, median (range) 136 (36–3,485) 124 (2.4–3,418) .24 140 (36–3,485) 126 (2.4–3,418) .35
Docetaxel treatment,6 mo, % 65 72 .12 70 66 .59
aSample size before propensity scorematching decreased to 257 and 303, respectively, after exclusions. Race, BMI, alkaline phosphatase, andmetastatic
sites were not covariates included in the propensity score matching.
Abbreviations:—, no data; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen.
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Grade $3 AEs were generally similar between the two study
arms, with the exception of increased left ventricular dys-
function and neutropenic fever among patients receiving mi-
toxantrone and increased anemia among patients receiving
prednisone alone. Signs of cardiotoxicity, however, may have
been monitored more frequently among patients receiving
mitoxantrone, given its known cardiac effects.
The current study has several important limitations.
Although our data were derived from randomized clinical
trials, our study population was not randomized between
treatment and control arms. Consequently, similar to
traditional observational studies, our analyses are subject
to bias from confounding. To overcome this limitation,
propensity score matching, based on previously described
predictors of survival in mCRPC, was used to minimize this
bias.Wewere unable to assess the influence ofmitoxantrone
on specific quality-of-life metrics because of a lack of
comparable patient-reported symptoms or quality-of-life
data from the two studies. Using available toxicity data,
however, we demonstrated an increased prevalence of
several important toxic effects among patients treated with
mitoxantrone, raising questions about its previously asserted
palliative benefits in the treatment of mCRPC. Our safety
analyses were limited in that we did not have access to data
distinguishing treatment-related AEs that led to dose re-
duction or delay in treatment. Furthermore, because of our
small sample size (396 patients), power was insufficient to
detect a significant difference in survival with mitoxantrone
therapy. Finally, the SUN 1120 group received 5 mg of
prednisone twice daily compared with 10 mg once daily in
the TROPIC group, but this difference is likely clinically
insignificant.
Our study is unique in thatwecoupledobservational CER
methodology with clinical trial data to answer a research
question distinct from the primary objectives for either
individual trial. By using data from comparator arms of two
large phase III studies, we overcame many of the inherent
limitations of standard retrospective comparative effec-
tiveness studies, which often have limited clinical infor-
mation regarding potentially important determinants of
outcomes such as comorbidities, toxicities of treatment,
and detailed data on treatment dose and schedule.
Combining traditional epidemiologic methods with clini-
cal trial data provides the ability to better control for
confounding and other sources of potential bias because
of the collection and availability of rich patient-level
baseline covariates and outcomes while managing biases
introduced from nonrandom comparisons through methods
such as propensity score matching.
To our knowledge, this study is the first to be published
using clinical trial data from the PDS online resource to
elucidate a current question in clinical oncology. In our study,
we found no significant survival benefit in the postdocetaxel
setting by adding mitoxantrone to prednisone in comparison
Figure 2. Kaplan-Meier estimates comparing overall survival between patients with docetaxel-refractory metastatic castrate-resistant
prostate cancer treated with mitoxantrone plus prednisone versus prednisone alone.
©AlphaMed Press 2015
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with prednisone alone. In addition, several important toxic
effects were more prevalent among patients treated
with mitoxantrone. This raises the question of whether
mitoxantrone should be considered a standard of care in this
setting for either routine clinical care or as a standard
comparator arm in post-taxane clinical trials. Additional
studies arewarranted to further evaluate thepalliative benefit
of mitoxantrone in this setting.
CONCLUSION
Our study illustrates the potential for CER studies using PDS or
similar repositories to answer questions for which prospective
studies may never be conducted.
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Table 2. Common hematologic and nonhematologic adverse events reported among patients who received mitoxantrone plus
prednisone versus prednisone alone
Adverse event
Mitoxantrone plus prednisone (n5 198) Prednisone (n5 198)
All grades Grade 2 Grade ‡3 All grades Grade 2 Grade ‡3
Nonhematologic
Asthenia 30 (15) 8 (4) 2 (1) 30 (15) 8 (4) 6 (3)
Fatigue 89 (45) 22 (11) 1 (,1) 52 (26) 25 (13) 3 (2)
Pain 23 (12) 10 (5) 2 (1) 20 (10) 12 (6) 6 (3)
Dyspnea 23 (12) 4 (2) 2 (1) 12 (6) 4 (2) —
Bone pain 36 (18) 20 (10) 3 (2) 32 (16) 19 (10) 6 (3)
Urinary tract infectiona 6 (3) 3 (2) 3 (2) 13 (7) 4 (2) 5 (3)
Back pain 58 (29) 30 (15) 2 (1) 44 (22) 17 (9) 3 (2)
Arthralgia 35 (18) 15 (8) 4 (2) 22 (11) 14 (7) 2 (1)
Nausea 64 (32) 8 (4) — 53 (27) 16 (8) 1 (,1)
Vomiting 24 (12) 5 (3) — 34 (17) 10 (5) 2 (1)
Pyrexia 18 (9) 4 (2) 1 (,1) 7 (4) 2 (1) 1 (,1)
Diarrhea 31 (16) 3 (2) 1 (,1) 35 (18) 8 (4) 1 (,1)
Hematuria 12 (6) 5 (3) 1 (,1) — — —
Urinary obstructionb 9 (5) 1 (,1) 7 (4) 10 (5) 4 (2) 4 (2)
Pain in extremity 29 (15) 10 (5) — 31 (16) 11 (6) 2 (1)
Confused state 3 (2) — 3 (2) 5 (3) — 4 (2)
Left ventricular dysfunctionc 17 (9) 5 (3) 2 (1) 1 (,1) 1 (,1) 1 (,1)
Pulmonary embolism 6 (3) — 6 (3) 4 (2) 1 (,1) 2 (1)
Pneumonia 3 (2) 1 (,1) 2 (1) 8 (4) 6 (3) 2 (1)
Peripheral neuropathy 33 (17) 4 (2) 3 (2) 15 (8) 2 (1) 4 (2)
Abdominal pain 9 (5) 3 (1) — 7 (4) 3 (1) —
Hematologic
Neutropeniad 20 (10) 10 (5) 9 (5) 1 (,1) — 1 (,1)
Febrile neutropenia 5 (3) — 5 (3) — — —
Leukopeniad 8 (4) 4 (2) 1 (,1) 1 (,1) 1 (,1) —
Anemia 19 (10) 9 (5) 1 (,1) 41 (21) 24 (12) 7 (4)
Thrombocytopeniad 8 (4) 5 (3) 1 (,1) 5 (3) 2 (1) —
Dataareshownasnumberofpatients (percentage)and include19adverseevents in theSUN1120withunknowndateofoccurrence.Adverseeventswere
graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events.
aIncludes cystitis and urosepsis.
bIncludes adverse events termed hydronephrosis, ureteric obstruction, urinary tract obstruction, urinary retention, post renal failure, or obstructive
uropathy.
cIncludes adverse events termed left ventricular dysfunction, ejection fracture abnormal, ejection fraction decreased, cardiotoxicity, or cardiac failure.
dIncludes “neutrophil count decreased,” “white blood cell count decreased,” and “platelet count decreased.”
Abbreviation:—, no data.
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